It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Chaperone-mediated autophagy (CMA) is a protein degradation pathway that eliminates soluble cytoplasmic proteins that are damaged, incorrectly folded, or targeted for selective proteome remodeling. However, the role of CMA in skeletal homeostasis under physiological and pathophysiological conditions is unknown. To address the role of CMA for skeletal homeostasis, we deleted an essential component of the CMA process, namely Lamp2a, from the mouse genome. CRISPR-Cas9-based genome editing led to the deletion of both Lamp2a and Lamp2c, another Lamp2 isoform, producing Lamp2AC global knockout (L2ACgKO) mice. At 5 weeks of age female L2ACgKO mice had lower vertebral cancellous bone mass compared to wild-type (WT) controls, whereas there was no difference between genotypes in male mice at this age. The low bone mass of L2ACgKO mice was associated with elevated RANKL expression and the osteoclast marker genes Trap and Cathepsin K. At 18 weeks of age, both male and female L2ACgKO mice had lower vertebral cancellous bone mass compared to WT controls. The low bone mass of L2ACgKO mice was associated with increased osteoclastogenesis and decreased mineral deposition in cultured cells. Consistent with these findings, specific knockdown of Lamp2a in an osteoblastic cell line increased RANKL expression and decreased mineral deposition. Moreover, similar to what has been observed in other cell types, macroautophagy and proteasomal degradation were upregulated in CMA-deficient osteoblasts in culture. Thus, an increase in other protein degradation pathways may partially compensate for the loss of CMA in osteoblasts. Taken together, our results suggest that CMA plays a role in vertebral cancellous bone mass accrual in young adult mice and that this may be due to an inhibitory role of CMA on osteoclastogenesis or a positive role of CMA in osteoblast formation or function.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Arkansas for Medical Sciences, Department of Physiology and Cell Biology, Little Rock, USA (GRID:grid.241054.6) (ISNI:0000 0004 4687 1637)
2 University of Arkansas for Medical Sciences, Center for Musculoskeletal Disease Research, Little Rock, USA (GRID:grid.241054.6) (ISNI:0000 0004 4687 1637); University of Arkansas for Medical Sciences, Division of Endocrinology, Little Rock, USA (GRID:grid.241054.6) (ISNI:0000 0004 4687 1637)
3 University of Arkansas for Medical Sciences, Bone Biomechanics, Histology and Imaging Core (BHIC), Little Rock, USA (GRID:grid.241054.6) (ISNI:0000 0004 4687 1637)
4 University of Arkansas for Medical Sciences, Center for Musculoskeletal Disease Research, Little Rock, USA (GRID:grid.241054.6) (ISNI:0000 0004 4687 1637); University of Arkansas for Medical Sciences, Genetic Models Core, Little Rock, USA (GRID:grid.241054.6) (ISNI:0000 0004 4687 1637)